arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aura Biosciences, Inc.

AURA
$6.34 ▼ -0.32 (-4.80%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aura Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $601.4M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -15.3% ↗
FCF / Share $-0.34 ↗
Trailing P/E —
Price / Book 2.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-33.69M
↓ -22.6% —
FCF / Share Free cash flow per share
$-0.34
↑ +22.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
11
Cash Quality ↓
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters